235.95
0.44%
-1.05
Pre-market:
235.84
-0.11
-0.05%
United Therapeutics Corp stock is currently priced at $235.95, with a 24-hour trading volume of 390.57K.
It has seen a -0.44% decreased in the last 24 hours and a -3.40% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $237.1 pivot point. If it approaches the $233.2 support level, significant changes may occur.
Previous Close:
$237.00
Open:
$236.83
24h Volume:
390.57K
Market Cap:
$11.10B
Revenue:
$2.33B
Net Income/Loss:
$984.80M
P/E Ratio:
13.00
EPS:
18.15
Net Cash Flow:
$747.60M
1W Performance:
-0.41%
1M Performance:
-3.40%
6M Performance:
+5.10%
1Y Performance:
+4.26%
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
301-608-9292
Address
1040 Spring Street, Silver Spring, MD
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
Feb-05-24 | Initiated | Leerink Partners | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Dec-06-22 | Initiated | UBS | Buy |
Dec-05-22 | Initiated | Goldman | Sell |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-20-22 | Reiterated | BofA Securities | Underperform |
Sep-19-22 | Resumed | Wedbush | Outperform |
Feb-11-22 | Initiated | BTIG Research | Neutral |
Jul-14-21 | Upgrade | Argus | Hold → Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-03-19 | Initiated | BofA/Merrill | Underperform |
Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
May-17-19 | Upgrade | UBS | Sell → Neutral |
May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-22-18 | Reiterated | Barclays | Underweight |
Jan-18-18 | Resumed | Credit Suisse | Underperform |
Dec-27-17 | Reiterated | Wedbush | Outperform |
Apr-27-17 | Reiterated | Wedbush | Outperform |
Mar-30-17 | Initiated | UBS | Sell |
Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
Zacks Investment Research
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Zacks Investment Research
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Zacks Investment Research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
United Therapeutics Corp Stock (UTHR) Financials Data
United Therapeutics Corp (UTHR) Revenue 2024
UTHR reported a revenue (TTM) of $2.33 billion for the quarter ending December 31, 2023, a +20.20% rise year-over-year.
United Therapeutics Corp (UTHR) Net Income 2024
UTHR net income (TTM) was $984.80 million for the quarter ending December 31, 2023, a +35.40% increase year-over-year.
United Therapeutics Corp (UTHR) Cash Flow 2024
UTHR recorded a free cash flow (TTM) of $747.60 million for the quarter ending December 31, 2023, a +12.64% increase year-over-year.
United Therapeutics Corp (UTHR) Earnings per Share 2024
UTHR earnings per share (TTM) was $19.84 for the quarter ending December 31, 2023, a +32.09% growth year-over-year.
United Therapeutics Corp Stock (UTHR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 24 '24 |
Sale |
238.81 |
3,600 |
859,730 |
130 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 23 '24 |
Option Exercise |
129.49 |
3,600 |
466,164 |
3,730 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 23 '24 |
Sale |
236.38 |
3,600 |
850,983 |
130 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 22 '24 |
Option Exercise |
129.49 |
3,600 |
466,164 |
3,730 |
DWEK RAYMOND | Director |
Apr 22 '24 |
Option Exercise |
88.03 |
3,000 |
264,090 |
4,750 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 22 '24 |
Sale |
236.47 |
3,600 |
851,298 |
130 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 19 '24 |
Option Exercise |
129.49 |
3,600 |
466,164 |
3,730 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 19 '24 |
Sale |
236.91 |
3,600 |
852,876 |
130 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 18 '24 |
Option Exercise |
129.49 |
3,600 |
466,164 |
3,730 |
ROTHBLATT MARTINE A | CHAIRPERSON & CEO |
Apr 18 '24 |
Sale |
237.91 |
3,600 |
856,462 |
130 |
About United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension; and a licensing and commercialization agreement with Collplant for 3D bioprinting of solid-organ scaffolds for human transplants. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Cap:
|
Volume (24h):